Identification of barriers to insulin therapy and approaches to overcoming them by Russell-Jones, D et al.
Syddansk Universitet
Identification of barriers to insulin therapy and approaches to overcoming them
Russell-Jones, D; Pouwer, Francois; Khunti, K
Published in:






Publisher's PDF, also known as Version of record
Document license
CC BY-NC-ND
Citation for pulished version (APA):
Russell-Jones, D., Pouwer, F., & Khunti, K. (2018). Identification of barriers to insulin therapy and approaches to
overcoming them. Diabetes, Obesity and Metabolism, 20(3), 488–496. DOI: 10.1111/dom.13132
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
R E V I EW AR T I C L E
Identification of barriers to insulin therapy and approaches
to overcoming them
David Russell-Jones MBBS1 | Frans Pouwer PhD2 | Kamlesh Khunti MD3
1Department of Diabetes and Endocrinology,
Royal Surrey County Hospital NHS
Foundation Trust, Guildford, UK
2Department of Psychology, University of
Southern Denmark, Odense, Denmark
3College of Medicine, Biological Sciences and
Psychology, Leicester Diabetes Centre,
University of Leicester, UK
Correspondence
Prof. Kamlesh Khunti, MD, Diabetes Research
Centre, University of Leicester, Leicester
Diabetes Centre, Leicester General Hospital,
Gwendolen Road, Leicester LE5 4PW, UK.
Email: kk22@leicester.ac.uk
Funding information
National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health
Research; Care East Midlands (CLAHRC EM);
Novo Nordisk
Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability of
numerous glucose-lowering therapies and clear guidelines for T2D management. Tackling clini-
cal or therapeutic inertia, where the person with diabetes and/or their healthcare providers do
not intensify treatment regimens despite this being appropriate, is key to improving patients’
long-term outcomes. This gap between best practice and current level of care is most pro-
nounced when considering insulin regimens, with studies showing that insulin initiation/intensi-
fication is frequently and inappropriately delayed for several years. Patient- and physician-
related factors both contribute to this resistance at the stages of insulin initiation, titration and
intensification, impeding achievement of optimal glycaemic control. The present review evalu-
ates the evidence and reasons for this delay, together with available methods for facilitation of
insulin initiation or intensification.
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1 | INTRODUCTION
The benefits of timely glycaemic control for reducing the risk of
micro- and macrovascular complications are well established,1–4 yet
many people with type 2 diabetes (T2D) remain in poor glycaemic
control.5 Diabetes care has improved in the USA,6 Europe7–9 and
elsewhere10 in recent decades, as reflected in the increased propor-
tion of people with diabetes meeting national glycaemic targets; how-
ever, there remains a substantial number of people with T2D who
have inadequate glycaemic control. In the UK, for example, a third of
people with T2D do not achieve glycated haemoglobin (HbA1c) levels
≤7.5% (59 mmol/mol).11 This is despite the latest guidelines recom-
mending intensification of current diabetes treatment if a person’s
individual HbA1c target is not achieved within 3 months,12 or within
3 to 6 months, after initiation.13 Delayed treatment intensification in
uncontrolled patients can increase the risk of diabetes-related compli-
cations in later life. For example, the 10-year follow-up of the UK
Prospective Diabetes Study showed that intensive glucose control
(sulphonylurea or insulin or, if obese, metformin) from diagnosis was
associated with significantly decreased risks of myocardial infarction,
death from any cause and microvascular disease.3 In addition, a retro-
spective cohort study revealed that a 1-year delay in treatment inten-
sification in patients with poor glycaemic control significantly
increased the risk of myocardial infarction (67%, hazard ratio confi-
dence interval [HR CI 1.39; 2.01], heart failure (64% [HR CI 1.40;
1.91]), stroke (51% [HR CI 1.25; 1.83]) and a composite endpoint of
cardiovascular events (62% [HR CI 1.46; 1.80]).14 This “dysglycaemic
legacy” can therefore have a profound effect on a patient’s life and it
is crucial that this is addressed.
Recent studies show that people often remain above target for
several years before treatment intensification.5 This is true of every
step in the treatment pathway, but clinical or therapeutic inertia
appears to be more pronounced when considering addition of insulin,
particularly in insulin-naïve people.5 Reasons for this can be related
to the healthcare professional (HCP) and/or the person with diabetes,
and differ depending on which stage of their treatment strategy a
person is at. Poor glycaemic control can be partly attributed to
delayed initiation of insulin (initiation inertia), lack of dose adjustment
(titration inertia) and delayed intensification (intensification inertia),
all of which constitute therapeutic inertia.15 The evidence and
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reasons for inertia at these three steps are discussed in further detail
below, together with the methods used to tackle barriers to insulin
optimization (Figure 1 and Table 1).16–43
2 | INERTIA WITH INITIATION OF INSULIN
TREATMENT
2.1 | Evidence of initiation inertia
There are a large number of studies that have found evidence of initi-
ation inertia, as reviewed by Khunti et al15,44 and Khunti and Millar-
Jones.5 For example, findings from the European INSTIGATE study
showed that the mean HbA1c level upon insulin initiation was
9.2%.45 In a UK cohort study in insulin-naïve people with T2D receiv-
ing oral antidiabetic drugs (OADs) who did not meet glycaemic tar-
gets, only 25% initiated basal insulin within ~2 years and 50% within
~5 years.46 Another UK study in 14 824 people with T2D (on ≥2
OADs) found that the median time from initiating the final OAD to
beginning insulin treatment was 7.7 years, despite a mean HbA1c
>8% (64 mmol/mol).47 Notably, only 847 (26.9%) of the 3153 partici-
pants with poor glycaemic control following initiation of their last oral
agent were prescribed insulin during the study. More recently, a ret-
rospective cohort study in >80 000 people in the UK revealed that
the median time for an OAD-treated participant between becoming
above target until insulin initiation ranged from 6.0 to 7.1 years.44
The evidence therefore suggests that insulin initiation is inappropri-
ately delayed for several years. The majority of studies on clinical or
therapeutic inertia in T2D have been conducted in the USA, the UK
and Canada; however, there are a small number of multinational
studies, such as the Study of Once Daily Levemir (SOLVE)48 and
Time2DoMore.49 Findings from the SOLVE study, involving 17 374
people globally, confirmed that initiation inertia is a global problem,
the extent of which varies between countries. For example, the UK
cohort of SOLVE had a higher baseline HbA1c at time of insulin initi-
ation, compared with the global population of SOLVE (9.8% vs 8.9%,
respectively), despite having a shorter duration of disease.48,50 In
addition, the proportion of people with HbA1c >9% at time of insulin
initiation varied from 23% (Poland) to 64% (UK and Turkey), suggest-
ing the level of inertia varies between countries.48
2.2 | Reasons for initiation inertia
The reasons that people with diabetes and HCPs often resist or post-
pone insulin initiation are complex and frequently overlap. For exam-
ple, both groups often have concerns regarding hypoglycaemia,
weight gain and adherence.51,52 A global survey of 1250 HCPs found
that 75.5% would treat more aggressively were it not for the risk of
hypoglycaemia with insulin,53 while “problematic hypoglycaemia” was
one of the most frequent patient-reported reasons for avoiding insu-
lin therapy in a survey of 708 insulin-naïve people with T2D.54 Simi-
larly, HCPs and people with diabetes worry that insulin regimens will
be too burdensome to adhere to,54 with 54.5% of HCPs (n = 1250)
and 27.6% of people with diabetes (n = 1530) citing “taking insulin at
prescribed time or with meals every day” as difficult.53 Weight gain is
another shared concern, and one that does not diminish as patients
become more insulin-experienced.55 When considering insulin ther-
apy, these issues can manifest as a negative conversation in which
HCPs delay insulin initiation while their patient has one last attempt
to improve their lifestyle.54 Consequently, people with diabetes may
perceive insulin therapy as an indication of failure, or as a punishment
for their unhealthy behaviours, rather than a solution to obtaining
glycaemic control.
The most problematic of patient-related barriers to insulin initia-
tion are largely covered above, but other barriers may be psychologi-
cal, including fear of injections and/or fear of self-measuring blood
glucose,56,57 and the misconception that quality of life will worsen
considerably.55 Concerns may vary from person to person, and may
be more severe in a person with depression. For example, a person
with diabetes is almost twice as likely to be diagnosed with depres-
sion as someone without diabetes and, unsurprisingly, these insulin-
related issues are more overwhelming to a patient with comorbid
depression.58 Comorbid depression is a predictor of poor health out-
comes in diabetes,59 yet depression only was not associated with
postponement of insulin initiation in two longitudinal studies.59,60
Nevertheless, individuals with both elevated levels of depression and
anxiety were less likely to start insulin therapy.60 The patients in this
particular group might have experienced insulin-related anxieties,
which could explain the apparent disparity between these findings,
but replication studies in this area are needed to test this hypothesis.
In other cases, HCPs can overestimate patient concerns, particularly
fear of injection, and further contribute to this barrier.61 In terms of
barriers solely relevant to the HCP, a lack of experience in initiating






























FIGURE 1 Barriers and solutions to therapeutic inertia. Floating
spheres can be considered as a general solution to all named barriers
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with primary care physicians being more likely to delay insulin initia-
tion vs specialists for these reasons.39,62–65
While hypoglycaemia and weight gain remain important side
effects of insulin therapy, the therapeutic landscape of diabetes is
continually evolving and many improvements to the absorption kinet-
ics66 and delivery67,68 of insulin therapy have been observed in
recent years, and will be advanced in ongoing and future studies. A
detailed look at the fundamental unmet needs with insulin therapy
and the advances required to progress towards an ideal agent for dia-
betes management are beyond the scope of the present review, but
the availability and application of recent developments is discussed
further in the following sections.
2.3 | Methods to tackle initiation inertia
As chronic disease management is now mainly the responsibility of
primary care, research has focused on how to best equip and educate
primary care physicians. One of the most successful methods so far
has been to restructure primary care such that insulin initiation is
assisted, or led, by a nurse practitioner.69 For example, a recent clus-
ter randomized controlled trial in Australia showed that a “Stepping
Up” model, which involved nurse-led insulin initiation, resulted in
increased insulin initiation rates (odds ratio 8.3 [95% CI 4.5; 15.4]),
greater HbA1c reductions (treatment contrast: −0.6% [95% CI –0.9;
−0.3], −6.6 mmol/mol [95% CI –9.8; −3.3]) and no deterioration in
emotional wellbeing.21 Results from other studies suggest similar suc-
cess would be observed in Europe70 and the USA.37 One reason why
nurse-led insulin initiation results in better outcomes compared with
usual care might be that nurses are better placed to help administer
and titrate insulin and to address any concerns as part of their ongo-
ing contact with patients for similar tasks/procedures, thereby
strengthening that relationship. In contrast, GPs might not see
patients as often and, when they do, the patient might have several
problems they wish to discuss in a single appointment, while GPs
TABLE 1 Barriers and solutions to clinical inertia at the insulin initiation, titration and intensification stages of diabetes management
Barrier Level
Stage of
inertia Potential solutions Examples
Fear of hypoglycaemia Patient Any DSME Gottfredson et al16
DAFNE-HART17,18
A study during Ramadan19
Mobile app-based interventions Glucool Diabetes, OnTrack Diabetes,
Dbees, Track3 Diabetes Planner20
Physician/System Any Nurse-led management Furler et al21
Physician Any Specialist feedback IPCAAD22
Physician Any Training MERIT23
Any Intensification Intensification of people on insulin with
agents associated with low risk of
hypoglycaemia
GLP-1RA24; SGLT2 inhibitors, DPP-4
inhibitors25
Weight gain Patient Any Mobile app-based interventions Few Touch Application26
Patient Any DSME DESMOND27
Patient Any Intensification of insulin with agents
associated with a low risk of weight
gain
GLP-1RA24; SGLT2 inhibitors, DPP-4
inhibitors25
Burdensome regimens Patient Any Mobile app-based interventions Use in adolescents28
Patient/Physician Intensification Fixed-ratio combination therapies Basal insulin/GLP-1RA combinations29,30;
basal–bolus combinations31
Patient/Physician Any Simpler titration algorithms Insight32 AT.LANTUS33 DUAL VI34
Patient Any DSME DESMOND27
Patient Initiation Insulin pen devices Meece35
Patient Initiation Insulin therapies with once-daily, flexible
dosing and lower day-to-day variability
Sorli and Heile36
Poor communication System Initiation Nurse-led management Stepping Up model21
System Any Nurse-led management Litaker et al37
Physician Any Liaison with/feedback from nurses and
specialists
Manski-Nankervis et al38; Zafar et al39
Severe psychological
insulin resistance
Patient Any Improved communication to allay patient
fears
Clark40
Anxiety and depression Patient Any Support from a mental HCP Clark40; Pouwer41; DESMOND27
Lack of time and
resources for GPs
System Any Nurse-led or nurse-assisted management Stepping Up model21; Manski-Nankervis
et al38
Specialist feedback IPCAAD42
Technology-based assistance Boren et al43
Abbreviations: AT.LANTUS, A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar;
DESMOND, Diabetes Education and Self-Management for Ongoing and Newly Diagnosed; DUAL, Dual Action of Liraglutide and IDeg in Type 2 diabetes;
IPCAAD, Improving Primary Care of African Americans with Diabetes; MERIT, Meeting Educational Requirements, Improving Treatment.
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only have a short time available to update patient records, diagnose
and prioritize next actions; therefore, the above-mentioned restruc-
turing of primary care might help divide time efficiently without
sacrificing or sabotaging the patient’s trust in their HCP and propa-
gating non-compliance. There is also a wealth of evidence that educa-
tion, in the form of either specialist feedback42 or computer-based
learning/reminders,22,43,71,72 facilitates timely intensification by pri-
mary care physicians and, therefore, improved glycaemic control in
patients. For example, a recent meta-analysis showed that informa-
tion technology-based interventions were associated with statistically
significant HbA1c reductions (mean treatment difference − 0.33%
[95% CI –0.40; −0.26], −3.6 mmol/mol [95% CI –4.4; −2.8], P < .001)
in people with T2D.73 Further education on the improvements in
basal insulin therapy and their devices, such as long-acting analogues
with lower day-to-day variability and lower risk of hypoglycaemia vs
older alternatives, can also help reduce psychological insulin
resistance.66,74–76 An important point to note is that education relies
on effective communication to succeed – both between HCPs and
between HCPs and patients.38 For instance, exploring patient beliefs
about insulin therapy early in the disease trajectory is key to tackling
psychological insulin resistance.57 Ideally, these discussions would
begin at, or soon after, diagnosis and would explain that insulin ther-
apy is ultimately required in the great majority of cases to control the
disease and avoid complications. HCPs should be able to allay their
patients’ concerns regarding burdensome regimens and quality of life
by describing the improvements made to insulin regimens, in terms of
devices and dosing, and sharing testimonials of people who have suc-
cessfully managed their T2D with insulin therapy. This should help
the person with diabetes come to terms with insulin therapy before
they require it, and avoid delays in initiation. The trend towards a less
negative appraisal of insulin therapy by insulin-treated people with
diabetes suggests patient fears can be resolved with further
information,20 but delays can be avoided by providing this informa-
tion soon after diagnosis. Indeed, improvements, in terms of achiev-
ing a combined outcome of HbA1c <9% (75 mmol/mol), LDL
cholesterol <7.2 mmol/L and systolic blood pressure < 140 mm Hg,
were observed when combining HCP and patient education vs physi-
cian feedback alone in one cluster randomized trial.77 These improve-
ments, albeit slight, were across a range of variables and might reflect
a significant change in prognosis. Effective communication is also par-
ticularly crucial when addressing concerns of people with T2D and
anxiety or comorbid depression; therefore, a psychologist with
knowledge of diabetes should be readily available to help with severe
cases of psychological insulin resistance in people with diabetes40 as
well as treating depression when required.41
3 | INERTIA WITH REGARD TO INSULIN
TITRATION
3.1 | Evidence of titration inertia
Studies indicate that once treatment with basal insulin has been initi-
ated, glycaemic control is still not achieved in the majority of
cases78,79 and that this is partly attributable to insufficient titration of
insulin.33,44 A study by Blak et al.,78 in 2012, revealed that only
17.3% of participants achieved HbA1c <7% (53 mmol/mol) after a
mean follow-up of 2.9 years, while 141 (41%) participants in a study
by Dale et al,79 in 2010, achieved the pre-2006/2007 UK Quality
and Outcomes Framework target of ≤7.4% (57 mmol/mol) after
36 months of basal insulin therapy. In addition, modest titration of
basal insulin in a real-world setting has been observed in studies from
Germany,80 New Zealand81 and China.82 This is in contrast to data
from the plethora of clinical trials74,75 that entail close monitoring by
trial staff of motivated participants following strict titration algo-
rithms.83 In terms of insulin omission, findings from a systematic
review indicated that the insulin adherence rate (the proportion of
doses taken as prescribed) among people with T2D was 62% to
64%.84 In people with T2D initiating insulin therapy, another report
found that 4.5% of people had unfilled prescriptions and a further
26% never obtained a refill.85
3.2 | Reasons for titration inertia
Many of the barriers that delay intensification with insulin continue
to pose a problem following initiation. For instance, there is often a
lack of HCP resources, assistance and education for patients regard-
ing effective titration.5 Ongoing patient fear of hypoglycaemia and
weight gain can result in under-titration,86 and concerns about impact
on daily life can result in insulin omission and infrequent self-
measured blood glucose testing by the patient.5,39,55 In addition,
HCPs might not adequately direct or encourage aggressive titration
in patients for whom this would be beneficial, either because of a
lack of resources or in response to patient concerns. It is not always
clear whether the lack of titration observed in real-world studies is as
a result of reluctance/inaction by the HCP or the patient, or
both.80–82 A recent systematic review of real-world factors affecting
adherence to insulin therapy in people with diabetes identified pre-
dictive factors for adherence vs non-adherence. Negative predictors
of adherence included being a student, needing a large number of
injections, diagnosis of T2D vs type 1 diabetes, and lower HbA1c
level. Positive predictors for adherence included support from a dia-
betes nurse specialist, switching from a traditional formulary scheme
to a value-based insurance design, hypoglycaemia awareness, follow-
ing a healthy diet, perceived self-efficacy, and previous experience of
liaison psychiatry or cognitive behavioural therapy.87
3.3 | Methods to tackle titration inertia
Alternative titration algorithms can simplify regimen complexity, and
thereby help patients to manage their diabetes more conveniently
and effectively. For example, patient-led titration using simple titra-
tion algorithms has resulted in greater HbA1c reductions vs
physician-led adjustment of either OADs (−1.55% vs −1.25%, −17 vs
−14 mmol/mol, P = .005; the INSIGHT study)32 or insulin glargine
(−1.22% vs −1.08%, −13 vs −12 mmol/mol, P < .001; AT.LANTUS).33
In addition to simpler titration algorithms, educational self-
management programmes for people with diabetes are key to opti-
mizing clinical outcomes for insulin-naïve and insulin-experienced
RUSSELL-JONES ET AL. 491
patients alike. Indeed, diabetes self-management education (DSME) is
an integral aspect of the latest guidelines for management of
T2D.12,88 A recent meta-analysis showed that mean change in HbA1c
was −0.74% (−8 mmol/mol) and −0.17% (−2 mmol/mol) for interven-
tion with DSME and control, respectively. Greater HbA1c reductions
were reported with DSME when contact with the patient numbered
≥10 hours and/or combined group and individual sessions.89 This
suggests that DSME helps patients to manage their diabetes treat-
ment and adopt positive behavioural changes. Other studies support
this,90 with one randomized pragmatic trial showing that structured
education (Diabetes Conversation Map™) resulted in a greater pro-
portion of patients achieving their American Association of Diabetes
Educators Self-Care Behaviours™ framework (AADE7) behavioural
goals at 3 months than was seen with usual care.91 Adherence, par-
ticularly in terms of aggressiveness or intensity of titration, is difficult
to quantify, but these studies do show that DSME is effective at
tackling one facet of titration inertia. Longer-term studies are
required to establish whether these changes in patient behaviours
are maintained, as there have been mixed results so far.27,92–94 There
are several new tools to help people manage their diabetes effec-
tively, which have an in-built dose adjustment algorithm for patients
with T2D receiving basal insulin.95,96 Full results are yet to be pub-
lished, but these devices could help a patient manage their insulin
regimen safely and more effectively, and require less contact time
with physicians. Furthermore, several mobile health applications for
diabetes self-management are available to help a patient manage
their food intake or insulin dose and aid intensification. Findings from
a recent systematic review involving 12 trials and 974 participants
showed that app-based interventions were associated with a clinically
significant reduction in HbA1c (treatment contrast 0.48% [95% CI
0.19; 0.77], −5 [95% CI 2; 8]) without excess adverse events. When
apps were grouped according to the presence/absence of different
education modules, mobile app-based interventions were associated
with significant HbA1c reductions when they included a complication
module and/or a structured display, but not when they included a
clinical decision-making function, suggesting that this module requires
improvement, with input from both the physician and user.97 Simi-
larly, studies on app-based interventions for elderly people with dia-
betes have yielded promising but varying results, depending on the
particular app used.98 Further adjustments and evaluation are
required to help realize the full potential of these novel tools, particu-
larly with respect to insulin management, which was not the primary
focus of many of these DMSE and app-based interventions.
4 | THERAPY INTENSIFICATION INERTIA
4.1 | Evidence of intensification inertia
As T2D progresses, intensification of basal insulin therapy may be
required. This might be addition of a bolus insulin dose in response to
prandial blood glucose excursions, or intensification with a non-
insulin agent in response to problems with weight gain, hypoglycae-
mia or in order to tackle additional underlying pathophysiological
defects of T2D.12 There are relatively few studies that investigate
inertia with insulin intensification, but similar delays have been
observed. Blak et al78 reported that treatment intensification in 3815
patients receiving basal insulin therapy was associated with high
HbA1c concentration (9.2% [77 mmol/mol] before intensification),
with only 4.7% of patients intensified, despite a low proportion (17%)
achieving HbA1c <7% (53 mmol/mol). A more recent retrospective
cohort study of 11 696 insulin-treated UK patients showed that less
than one-third (31%) of patients who had HbA1c ≥7.5% (≥59 mmol/
mol) had their treatment intensified, and the median time from basal
insulin initiation to treatment intensification was 3.7 years [95% CI
3.4; 4.0]. Of all patients for whom treatment was intensified, 50%
were intensified with bolus insulin; 43% were intensified with premix
insulin and 7.4% were intensified with glucagon-like peptide-1 recep-
tor agonists (GLP-1RAs).99
4.2 | Reasons for intensification inertia
The reasons for delayed intensification can vary depending on which
strategy is being considered. When discussing addition of prandial
doses of insulin, concerns are often centred around the risk of hypo-
glycaemia and weight gain, treatment adherence and the impact of
more complex or intensive regimens on the patient’s quality of
life.36,39 In addition, injection-related anxiety remains an issue for
insulin-experienced patients, as demonstrated by results of a ques-
tionnaire completed by 115 insulin-treated people with type 1 diabe-
tes or T2D. The resulting injection anxiety scores were poor (≥3) in
28% of patients and were associated with higher levels of general
anxiety (Kendall’s tau-a 0.30 [95% CI 0.19; 0.41]; P < .001).100 As
with initiation inertia, HCPs can also have concerns that result in
intensification inertia. For example, fear of adverse side effects with
insulin is a concern often shared by HCPs and patients,5,101 and
which can deter HCPs from prescribing an additional insulin injection.
Continued uptitration of basal insulin may also be favoured over an
additional agent because the HCP does not have adequate time avail-
able to initiate or does not believe the patient will manage a more
complex regimen.5
4.3 | Methods to tackle intensification inertia
In addition to the improvements in insulin products discussed earlier,
several newer medications for T2D provide alternatives to insulin
intensification. These include drugs of the incretin class (GLP-1RAs
and dipeptidyl peptidase-4 [DPP-4] inhibitors) and sodium-glucose
co-transporter-2 (SGLT2) inhibitors, all of which are associated with
a low rate of hypoglycaemia and either weight loss (GLP-1RAs,
SGLT2 inhibitors) or weight neutrality (DPP-4 inhibitors).12 Impor-
tantly, basal insulins and GLP-1RAs have been combined in a single
pen in titratable, fixed-ratio co-formulations such as insulin degludec/
liraglutide (IDegLira)29,30,102,103 and insulin glargine U100/lixisenatide
(iGlarLixi).104–106 Both products are injected once daily, allowing insu-
lin/GLP-1RA intensification without additional daily injections. One
important difference is that two co-formulations of iGlarLixi were
developed; Pen A, which delivers 10–40 units (U) at a ratio of 2 U
IGlar:1 μg lixisenatide in a single injection, and Pen B, which delivers
30–60 U at a ratio of 3 U IGlar:1 μg lixisenatide.107,108 Both are
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approved for use in Europe106 but only Pen B, with a starting dose of
15 U, is approved for use in the USA.105 It is important to note that
there are few real-world data published on these relatively recently
available therapies,109,110 so it is not known whether they are effec-
tive at tackling therapeutic inertia. It is sensible to assume, however,
that there would be less resistance from patients and HCPs to using
an insulin-containing combination therapy with a lower risk of side
effects compared with complex insulin regimens, when appropriate.
To take full advantage of the advances in diabetes therapy, many of
the methods discussed with regard to initiation inertia – such as edu-
cation of, and effective communication between, HCPs and patients
– would also warrant employment at this stage.
5 | SYSTEM-LEVEL BARRIERS TO
APPROPRIATE INSULIN INITIATION AND
INTENSIFICATION
System-level barriers affect all stages of insulin management, and
indeed healthcare in general. These barriers have been discussed
briefly in earlier sections and are summarized here. As mentioned ear-
lier, the development of new therapies and devices to meet the
unmet needs of diabetes management is key to tackling barriers to
initiation and intensification inertia. However, the relative expense of
these developments, a system-level barrier, will also be paramount in
determining their impact on clinical inertia. The adequacy, according
to HCPs, of other medical resources for diabetes management has
been evaluated in the two multinational Diabetes Attitudes, Wishes
and Needs (DAWN) studies.62,111 Key findings of DAWN2, which
surveyed 4785 HCPs from 17 countries, were that the majority of
HCPs believed that major improvements were required in DSME
(60%), specialist nurse availability (64%), psychological support (63%)
and earlier diagnosis and treatment (68%).111 Unsurprisingly, a large
amount of variation was observed between countries that have dif-
ferent healthcare models, needs and services, but it is still possible to
glean the relative merit of various system reforms. Healthcare ser-
vices in general are in urgent need of reform to tackle the changing
trends in population and disease burden, and these changes will
undoubtedly affect diabetes management. Several possibilities, such
as the restructuring of primary care, implementation of various edu-
cational platforms and support for self-care, have been discussed
here but few have been incorporated into the latest guidelines for
management of diabetes. Further investigations, particularly in real-
world settings, are required before they can be applied on a wider
scale.
6 | CONCLUSION
Therapeutic inertia in T2D is a global issue that impedes achievement
of glycaemic control, particularly in patients requiring insulin therapy.
Reasons for this span the patient, physician and system levels and
include misconceptions surrounding insulin therapy, lack of experi-
ence in primary care with managing insulin regimens, affordability,
and lack of time, resources and/or motivation to optimize insulin use.
Another major issue is poor communication, which can hinder the
exchange of patient fears and potential solutions if communication is
lacking, or exacerbate patient fears if communication is unhelpful, for
example, when insulin initiation is implied to be a punishment for
sub-optimal lifestyle management. Improvements to available guide-
lines and therapies for management of T2D have been made in
recent years, but several strategies are required to improve education
of, and communication between HCPs and patients, before these can
be employed effectively. Promising results have been observed with
implementation of DSME, using algorithms such that titration can be
patient-driven, developing web-based titration applications, and facili-
tating nurse-led insulin management. Some strategies are simpler and
less time-intensive than others to implement, but all focus on improv-
ing the awareness of the impact of clinical or therapeutic inertia. Fur-
ther randomized controlled trials with larger samples and
observational studies in a real-world setting are required to establish
the relative efficacy of different models of care and their long-term
success.
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